This should be further examined in clinical trials and may influence future trial design for galectin-3 inhibitors, including their subgroup analysis, as squamous cell carcinoma and non-squamous cell carcinoma (including adenocarcinoma) are currently treated with different regimens [42,43,44,45]. This evidence concerns the gene LGALS3 and squamous cell carcinoma.